The acquisition of Biotheus by BioNTech provides the company with full global rights to a promising bispecific antibody, BNT327/PM8002, which is under study for various oncology indications. This strategic acquisition is expected to enhance BioNTech's oncology pipeline, potentially leading to new treatments and strengthening its market position. The positive market reaction, as indicated by the stock price increase, reflects investor confidence in the potential benefits of this acquisition.